Ambu A/ S stock (DK0060946788): investors weigh turnaround after latest half-year results

Ambu A/S has presented fresh half-year figures and an updated outlook, keeping the focus on its single-use endoscopy strategy and profitability path. What the new numbers mean for growth and risks in this medtech stock, especially for international and US-focused investors.

Ambu A/S has remained in the spotlight after publishing its results for the first half of its 2024/25 financial year, together with an update on its single-use endoscopy strategy and profitability ambitions, according to Ambu investor update as of 05/2025. The Danish medical technology group highlighted revenue trends across segments and reiterated its focus on scaling its endoscopy platform while improving margins, as reported by Reuters as of 05/2025.

As of: 25.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Ambu
• Sector/industry: Medical technology, single-use endoscopy
• Headquarters/country: Ballerup, Denmark
• Core markets: Hospitals and clinics in Europe, North America and selected international markets
• Key revenue drivers: Single-use endoscopes, anesthesia and patient monitoring products
• Home exchange/listing venue: Nasdaq Copenhagen (ticker: AMBU-B)
• Trading currency: Danish krone (DKK)

Ambu A/S: core business model

Ambu A/S develops and sells medical devices with a focus on single-use, or disposable, endoscopes and other hospital products that are used in diagnostic and therapeutic procedures, according to the company’s description in its investor materials, as outlined by Ambu investors as of 04/2025. The group positions itself as a pioneer in single-use endoscopy, aiming to replace reusable devices that require complex cleaning and reprocessing, which can be costly and time-consuming for hospitals.

In practice, the business model revolves around supplying hospitals and clinics with endoscopy systems that combine single-use endoscope devices with visualization and processing units, together with related accessories. This model generates revenue both from equipment sales and from ongoing demand for disposable devices as procedures are performed, as highlighted in the company’s financial reports summarised by Ambu financials as of 11/2024. For investors, this creates a blend of one-off and recurring revenue characteristics.

Ambu divides its activities into different business areas, including visualisation, anesthesia and patient monitoring and diagnostics. Visualisation, which includes single-use endoscopes for pulmonology, urology, ear-nose-throat and other specialties, has become the main growth driver in recent years, according to the company’s segment disclosures in its reports, as noted by Ambu annual report as of 11/2024. The anesthesia and patient monitoring segment provides a broader base of hospital products, underpinning the group’s presence in operating rooms and intensive care units.

From a strategic perspective, Ambu aims to win market share by offering single-use devices that can simplify workflows, reduce infection risk and free up resources in hospitals. The company emphasizes that disposable endoscopes remove the need for complex cleaning procedures and may help address concerns about cross-contamination and hospital-acquired infections, themes frequently referenced in management presentations referenced by Ambu presentations as of 03/2025.

For international and US-focused investors, Ambu’s business model is particularly relevant because it targets large healthcare systems where procedural volumes are high and operational efficiency is a key priority. The US market plays an important role as a growth region for single-use endoscopy, according to comments from the company in its North America strategy updates, as summarized by Ambu North America update as of 10/2024.

Main revenue and product drivers for Ambu A/S

The main revenue driver for Ambu A/S in recent years has been its visualisation business, which includes a broad portfolio of single-use endoscopes for different disciplines. The company has launched successive product generations aiming to improve image quality, maneuverability and ease of use, contributing to adoption in pulmonology and other areas, as outlined in the product pipeline overview published by Ambu products overview as of 02/2025. These launches often target specific procedures, such as bronchoscopy or urological interventions.

Beyond visualisation, anesthesia products – including laryngeal masks and related airway management devices – provide another important revenue stream. This area benefits from Ambu’s long-standing presence in anesthesia and its relationships with hospital procurement departments, according to the segment commentary in earlier annual reports documented by Ambu annual report as of 11/2023. Patient monitoring and diagnostics products, such as electrodes and sensors, further diversify the portfolio and can support a steadier demand profile across hospitals.

In its most recent half-year report for the 2024/25 financial year, Ambu reported continued growth in single-use endoscopy volumes, while also discussing margin development and cost initiatives, according to the company’s H1 release described by Ambu H1 2024/25 results as of 05/2025. In that report, management pointed to pricing, mix effects and productivity measures as key factors influencing profitability. For investors, these elements are central when assessing how revenue growth may translate into operating earnings over time.

The US market is a particular focus in Ambu’s growth plans, as large hospital systems can drive high procedure volumes and uptake of single-use solutions. The company has highlighted increased penetration in U.S. pulmonology and other specialties as a growth vector, based on comments in its North America updates summarised by Ambu North America update as of 10/2024. For US investors following medtech trends, Ambu’s positioning in this market can influence both its revenue outlook and its strategic relevance compared with domestic competitors.

Another revenue driver is the underlying trend towards single-use medical devices within infection prevention and hospital hygiene policies. Regulatory and guideline developments in various countries have placed increased emphasis on infection control and process reliability, which can support the case for disposable devices, according to sector commentary from major healthcare research providers summarized in trade publications and cited in Ambu’s investor communications, as referenced by Ambu industry trends overview as of 09/2024.

Conclusion

Ambu A/S continues to position itself as a specialist in single-use endoscopy and related hospital products, with the latest half-year figures drawing renewed attention to its revenue growth and margin trajectory. The company’s focus on scaling visualisation, controlling costs and expanding in key markets such as the United States remains central to its equity story, as laid out in its recent investor communications, including the H1 2024/25 report documented by Ambu H1 2024/25 results as of 05/2025. For US and international investors following medtech trends, the balance between growth opportunities, competitive dynamics and execution risks will likely remain key considerations when monitoring this Danish stock.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.